Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but a substantial proportion of patients either do not respond to treatment or lose response over time. Drug immunogenicity, manifested as the formation of anti-drug antibodies (ADAb), constitute a significant cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gehin, Johanna Elin, Goll, Guro Løvik, Brun, Marthe Kirkesæther, Jani, Meghna, Bolstad, Nils, Syversen, Silje Watterdal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649489/
https://www.ncbi.nlm.nih.gov/pubmed/36315391
http://dx.doi.org/10.1007/s40259-022-00559-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649489/
https://www.ncbi.nlm.nih.gov/pubmed/36315391
http://dx.doi.org/10.1007/s40259-022-00559-1

Ejemplares similares